Sickle cell disease

An in-depth report on the causes, diagnosis, and treatment of sickle cell disease.

I Would Like to Learn About:

Related Reports

Pneumonia

References

Anie KA, Green J. Psychological therapies for sickle cell disease and pain. Cochrane Database Syst Rev. 2015;(5):CD001916. PMID: 25966336 pubmed.ncbi.nlm.nih.gov/25966336/.

Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017;376(5):429-439. PMID: 27959701 pubmed.ncbi.nlm.nih.gov/27959701/.

Azar S, Wong TE. Sickle cell disease: a brief update. Med Clin North Am. 2017;101(2):375-393. PMID: 28189177 pubmed.ncbi.nlm.nih.gov/28189177/.

Brandow AM, Carroll CP, Creary S, et al. American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain. Blood Adv. 2020;4(12):2656-2701. PMID: 32559294 pubmed.ncbi.nlm.nih.gov/32559294/.

DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554-1588. PMID: 32298430 pubmed.ncbi.nlm.nih.gov/32298430/.

Dixit R, Nettem S, Madan SS, et al. Folate supplementation in people with sickle cell disease. Cochrane Database Syst Rev. 2018;3:CD011130. PMID: 29546732 pubmed.ncbi.nlm.nih.gov/29546732/.

Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Doree C, Abboud MR. Interventions for preventing silent cerebral infarcts in people with sickle cell disease. Cochrane Database Syst Rev. 2017;5:CD012389. PMID: 28500860 pubmed.ncbi.nlm.nih.gov/28500860/.

Hebbel RP, Vercellotti GM. Pathobiology of sickle cell disease. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 41.

Hirst C, Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev. 2014;(11):CD003427. PMID: 25375222 pubmed.ncbi.nlm.nih.gov/25375222/.

Hussein N, Weng SF, Kai J, Kleijnen J, Qureshi N. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease. Cochrane Database Syst Rev. 2015;(8):CD010849. PMID: 26264938 pubmed.ncbi.nlm.nih.gov/26264938/.

Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. PMID: 29542687 pubmed.ncbi.nlm.nih.gov/29542687/.

Klings ES, Machado RF, Barst RJ, et al. An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease. Am J Respir Crit Care Med. 2014;189(6):727-740. PMID: 24628312 pubmed.ncbi.nlm.nih.gov/24628312/.

Liem RI, Lanzkron S, D Coates T, et al. American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. Blood Adv. 2019;3(23):3867-3897. PMID: 31794601 pubmed.ncbi.nlm.nih.gov/31794601/.

Machado RF, Gladwin MT. Pulmonary complications of hematologic diseases. In: Broaddus VC, Mason RJ, Ernst JD, et al, eds. Murray and Nadel's Textbook of Respiratory Medicine. 6th ed. Philadelphia, PA: Elsevier Saunders; 2016:chap 94.

Martí-Carvajal AJ, Conterno LO, Knight-Madden JM. Antibiotics for treating acute chest syndrome in people with sickle cell disease. Cochrane Database Syst Rev. 2015;(3):CD006110. PMID: 25749695 pubmed.ncbi.nlm.nih.gov/25749695/.

McGann PT, Nero AC, Ware RE. Clinical features of ß-thalassemia and sickle cell disease. Adv Exp Med Biol. 2017;1013:1-26. PMID: 29127675 pubmed.ncbi.nlm.nih.gov/29127675/.

Nevitt SJ, Jones AP, Howard J. Hydroxyurea (hydroxycarbamide) for sickle cell disease. Cochrane Database Syst Rev. 2017;4:CD002202. PMID: 28426137 pubmed.ncbi.nlm.nih.gov/28426137/.

Niihara Y, Smith WR, Stark CW. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease. N Engl J Med. 2018;379(19):1880. PMID : 30403943 pubmed.ncbi.nlm.nih.gov/30403943/.

Piel FB, Steinberg MH, Rees DC. Sickle Cell Disease. N Engl J Med. 2017;376(16):1561-1573. PMID: 28423290 pubmed.ncbi.nlm.nih.gov/28423290/.

Qureshi A, Kaya B, Pancham S, et al. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease: A British Society for Haematology Guideline. Br J Haematol. 2018;181(4):460-475. PMID: 29732531 pubmed.ncbi.nlm.nih.gov/29732531/.

Rana S, Houston PE, Wang WC, et al. Hydroxyurea and growth in young children with sickle cell disease. Pediatrics. 2014;134(3):465-472. PMID: 25157002 pubmed.ncbi.nlm.nih.gov/25157002/.

Roy NB, Fortin PM, Bull KR, et al. Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev. 2017;7:CD012380. PMID: 28672087 pubmed.ncbi.nlm.nih.gov/28672087/.

Saunthararajah Y, Vichinsky EP. Sickle cell disease: clinical features and management. In: Hoffman R, Benz EJ, Silberstein LE, et al, eds. Hematology: Basic Principles and Practice. 7th ed. Philadelphia, PA: Elsevier; 2018:chap 42.

Smith-Whitley K, Kwiatowski JL. Hemoglobinopathies. In: Kliegman RM, Lye PS, Bordini BJ, Toth H, Basel D, eds. Nelson Pediatric Symptom-Based Diagnosis. Philadelphia, PA: Elsevier; 2018:chap 489.

Vichinsky E, Hoppe CC, Ataga KI, et al. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019;381(6):509-519. PMID: 31199090 pubmed.ncbi.nlm.nih.gov/31199090/.

Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311-323. PMID: 28159390 pubmed.ncbi.nlm.nih.gov/28159390/.

Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312(10):1033-1048. PMID: 25203083 pubmed.ncbi.nlm.nih.gov/25203083/.

BACK TO TOP

Review Date: 6/29/2020  

Reviewed By: Todd Gersten, MD, Hematology/Oncology, Florida Cancer Specialists & Research Institute, Wellington, FL. Review provided by VeriMed Healthcare Network. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.

ADAM Quality Logo

A.D.A.M., Inc. is accredited by URAC, for Health Content Provider (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics. This site complies with the HONcode standard for trustworthy health information: verify here.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2020 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.

A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.